Valneva SE (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Valneva SE (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Valneva SE (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Valneva SE (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 27, 2016
39 pages — Published Sep 27, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Valneva SE (Valneva) is a biotechnology company that develops and produces vaccines and antibodies. The companys vaccinations include Japanese encephalitis vaccine, IXIARO and JESPECT, JEEV, EB66 pseudomonas aeruginosa, pandemic influenza, clostridium difficile, EB66 human programs, lyme disease, tuberculosis vaccine, EB66 veterinary programs, and antibodies. It offers VIVA|Screen technology, a platform for the discovery of fully human monoclonal antibodies isolated from blood cells of individuals.

Valneva SE (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics a

  
Source:
Document ID
GDPH456494D
Country
Industry
Ticker
VLA=FR
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Valneva SE, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201642
Valneva SE, Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201661
Valneva SE, Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201671
Valneva SE, Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201681
Valneva SE, Medical Devices Deals, 2010 to YTD 201691
Valneva SE, Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016102
Valneva SE, Pharmaceuticals &Healthcare, Deal Details1223
  Venture Financing121
    Valneva to Secure USD18 Million from Funds Managed by Athyrium121
    BliNK Biomedical Raises Funds through Series A Venture Financing132
    Valneva Austria Raises US$30 Million In Venture Financing151
  Partnerships161
    Seqirus Enters into Distribution Agreement with Valneva161
    Valneva Enters into R&D Agreement with GlaxoSmithKline171
    Valneva Enters into Distribution Agreement with PaxVax181
    PaxVax Enters into Distribution Agreement with Valneva191
    Valneva Forms Joint Venture with BliNK Therapeutics201
  Licensing Agreements211
    Valneva Enters into Licensing Agreement with Jianshun Biosciences211
    Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant221
    Valneva to Enter into Licensing Agreement with Pharma Company231
    Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer241
    GeoVax Labs Enters into Licensing Agreement with Valneva251
    Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine261
    Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line271
    Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine281
  Equity Offering291
    Valneva Raises USD54 Million in Rights Offering292
    Valneva Completes Rights Offering Of Shares For US$53.5 Million312
  Asset Transactions331
    Valneva To Sell Clinical Manufacturing Operations Facility To Biological E331
  Acquisition341
    Valneva Acquires Crucell Sweden for USD54 Million341
Valneva SE - Key Competitors351
Key Employees361
Locations And Subsidiaries372
  Head Office371
  Other Locations &Subsidiaries372
Appendix391
  Methodology391
  About GlobalData391
  Contact Us391
  Disclaimer391

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Valneva SE (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Valneva-SE-VLA-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-23250>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Valneva SE (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Valneva-SE-VLA-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-23250>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research